Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: New Constructs, LLC
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: S&P Capital IQ Quantitative Report
$127.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

AMAG Pharmaceuticals Inc raises FY 2014 revenue guidance; lowers FY 2014 net income guidance


Tuesday, 29 Jul 2014 07:00am EDT 

AMAG Pharmaceuticals Inc:Increases FY 2014 total revenue guidance of between $93 mln and $102 mln, including U.S. Feraheme net product sales of $80 mln to $87 mln, revised upward from the company's previous estimate of $75 mln to $85 mln.Increases FY 2014 net loss guidance to $12 mln to $14 mln from the company's previous estimate of $10 mln to $12 mln.FY 2014 revenue of $94 mln and net income of $(0.6) mln - Thomson Reuters I/B/E/S. 

Related Company News

Company Quote

23.02
0.15 +0.66%
4:00pm EDT